Symphony Robotics Licenses New Robotics Technology to Fight Brain Tumors
Symphony Robotics has secured an exclusive worldwide license from Case Western Reserve University (CWRU) for a novel MRI-guided, magnetically actuated, flexible micro robotic arm technology. This groundbreaking system navigates non linear trajectories, enabling precise, micro-invasive surgeries with real-time image guidance. CWRU researchers and faculty have been instrumental in the development and advancement of this innovation.
Symphony Robotics is now advancing the patents-pending technology, which combines micro-robotic arms, real-time computer vision, and state-of-the-art artificial intelligence. The initial focus is to provide neurosurgeons with enhanced capabilities for complex microsurgical procedures, targeting brain cancer—particularly Glioblastoma Multiforme (GBM)—as well as epilepsy. The ultimate goal is to reduce incision and craniotomy sizes to less than 4 millimeters, representing a tenfold reduction compared to current clinical norms.
GBM is among the most aggressive and challenging brain cancers to treat. Existing surgical methods, such as craniotomies, are highly invasive, requiring large skull openings and posing significant risks, including trauma to healthy brain tissue and delays in follow-up treatments such as radiation, chemotherapy, or drug delivery. Other methods such as laser ablation only support a limited and partial treatment option. Symphony Robotics' flexible, non-linear micro robotic arm aims to enable extended and precise access to deep seated lesions while protecting surrounding eloquent tissue, offering the potential to improve outcome and quality of life for GBM patients.
Symphony Robotics founder and CEO, Mordechai (Moty) Avisar, stated: 'Our technology will introduce unprecedented advancements in neurosurgery. The potential to enhance surgical precision and improve patient outcomes is truly groundbreaking. Neurosurgeons will be able to perform highly targeted procedures on deep-seated pathologies through significantly smaller surgical openings—down to the micro level—while navigating complex, geometrically dispersed pathologies with greater safety and accuracy.'
Dr. Robert Louis of the Pickup Family Neurosciences Institute, Hoag Memorial Hospital in Newport Beach, California, commented: 'The micro-robotic arm's MRI-compatible maneuverability will allow neurosurgeons to perform complete ablations through a single micro-opening, even in lesions that are otherwise untreatable due to their location and/or shape. This innovation could reduce the insertion hole size from something akin to a coffee cup to that of a small stirring straw. Could craniotomies become obsolete? It certainly seems possible.'
CWRU has spent over a decade developing the underlying micro robotic arm technology, supported by funding from the National Institutes of Health (NIH) and the National Science Foundation (NSF). The University plans to continue collaborating with Symphony Robotics on further development.
Symphony's ultra-maneuverable micro-robotic technology is built on two proprietary advancements: leveraging the magnetic capabilities of MRI systems for non-linear navigation of the micro robotic arms and enabling real-time guidance with MRI's high resolution imaging. The company is preparing for nationwide testing in collaboration with leading partner hospitals.This product is not available for clinical use and has not been cleared for use by the US FDA.
About Symphony Robotics
Symphony Robotics (SR) is leading the development and commercialization, of an advanced, ultra-maneuverable surgical micro-robot designed to revolutionize neurosurgery, particularly for treating Glioblastoma Multiforme (GBM). The core of this technology is a non-linear, flexible micro-robotic arm capable of navigating through complex brain structures with unparalleled precision. This groundbreaking innovation integrates real-time, MRI-guided visualization with cutting-edge AI and computer vision, giving neurosurgeons enhanced control over delicate procedures.
Symphony Robotics (SR) is leading the development and commercialization, of an advanced, ultra-maneuverable surgical micro-robot designed to revolutionize neurosurgery, particularly for treating Glioblastoma Multiforme (GBM). The core of this technology is a non-linear, flexible micro-robotic arm capable of navigating through complex brain structures with unparalleled precision. This groundbreaking innovation integrates real-time, MRI-guided visualization with cutting-edge AI and computer vision, giving neurosurgeons enhanced control over delicate procedures.
SOURCE: Symphony Robotics
Copyright Business Wire 2025.
PUB: 02/11/2025 10:11 AM/DISC: 02/11/2025 10:12 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a day ago
- Medscape
MRI-Led Surveillance Stratifies Prostate Cancer Risk
In a cohort study of patients with prostate cancer, MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence of secondary Gleason pattern 4 at baseline were associated with higher rates of progression and treatment initiation. METHODOLOGY: Researchers analysed 1150 patients who started active surveillance between February 2000 and July 2023, including those with a Gleason score (GS) ≤ 3 + 4, prostate-specific antigen (PSA) < 20 ng/mL, and at least two MRI scans. Participants underwent PSA testing three to four times in the first year, followed by biannual testing; MRI was performed at baseline and 12 months, with an additional MRI scan performed at 24 months for those with MRI-visible lesions at baseline. Patients were stratified into four groups on the basis of baseline risk factors, including GS (3 + 3 vs 3 + 4) and MRI visibility ("non-visible disease" vs "visible disease"). The primary outcome was event-free survival, with an event defined as the detection of GS ≥ 4 + 3 or the initiation of any prostate cancer treatment. The median follow-up duration was 64 months per person overall and 72 months for 732 patients without an event. At baseline, 64% of patients had GS 3 + 3 and 36% had GS 3 + 4; 49% of those with GS 3 + 4 had MRI-visible disease. TAKEAWAY: Event-free survival rates varied significantly on the basis of the risk group, with 5-year rates of 91% for non-visible GS 3 + 3, 71% for MRI-visible GS 3 + 3, 71% for non-visible GS 3 + 4, and 44% for MRI-visible GS 3 + 4 disease. Among 487 patients who underwent follow-up biopsies, histological upgrade to GS ≥ 4 + 3 occurred in 67 patients; non-visible GS 3 + 3 cases had 5- and 10-year rates of 1.2% and 6.1%, respectively, for histological progression to GS ≥ 4 + 3, while the rates were 17% and 43% for those with MRI-visible GS 3 + 4 disease at baseline, respectively. Progression to nodal or bone metastases was observed in 10 patients, occurring only in those who had declined recommended follow-up MRI and/or biopsies. The 10-year rate of commencing treatment was 28% for those with non-visible GS 3 + 3 disease vs 85% for those with MRI-visible GS 3 + 4 disease and 46% for those with non-visible GS 3 + 4 disease vs 54% for those with MRI-visible GS 3 + 3 disease. IN PRACTICE: "Results from our cohort suggest that AS [active surveillance] patients can be monitored safely with MRI, and the decision to biopsy was based on MRI findings and PSA changes. Prospective, multicentre, clinical trials are required and currently being designed to further evaluate this approach," the authors wrote. SOURCE: This study was led by Cameron Englman, Division of Surgery & Interventional Science, University College London, London, England. It was published online on May 27, 2025, in European Urology . LIMITATIONS: Compared with time-based biopsy protocols, the MRI-led risk-adapted approach may underestimate histological progression. Additionally, as a cohort study without a strict protocol, practice evolved alongside contemporary pathology and radiology standards, with MRI quality, reporting standards, and the definition of radiological progression varying over time, particularly improving after the adoption of the PRECISE recommendations in 2016. DISCLOSURES: This study did not receive any specific funding. Several authors reported receiving consulting fees and grants and having other ties with various sources.
Medscape
a day ago
- Medscape
Radiology Workforce Shortages Impacting Cancer Care
A chronic shortage of radiologists and oncologists is putting patients in the UK at risk, a new report found. The annual workforce census by the Royal College of Radiologists (RCR) warned that the safe delivery of NHS cancer care is becoming 'increasingly impossible' due to an escalating shortfall of doctors coupled with rising demand for care. In 2024, the UK had a 29% shortfall of clinical radiologists, with regional gaps ranging from 25% in Scotland to 32% in Wales. The workforce grew by 4.7% that year — less than in 2023, when it increased by 6.3%. The college forecasts the radiologist shortfall will reach 39% by 2029. Oncology Under Strain Clinical oncologists are also in short supply, with a current 15% gap expected to rise to 19% by 2029. This is despite a 5.4% increase in the workforce in 2024—the strongest growth since 2018. The RCR reported that 23% of cancer centres were experiencing recruitment freezes, making it harder to meet growing demand. Demand Continues to Outpace Capacity The shortages threaten the government's plans to cut waiting times and improve cancer outcomes. In 2024, demand for computerised tomography (CT) and magnetic resonance imaging (MRI) grew by 8%, but workforce growth did not keep pace. Every radiology leader surveyed last year reported delays to diagnostic scans caused by staff shortages. Nine in 10 radiology team leaders reported that patients were waiting longer to start treatment, while seven in 10 expressed concern that staff shortages were putting patient safety at risk – down slightly from 85% in 2023. Chronic problems such as workforce shortages, reporting backlogs, and staff vacancies remain too high, according to Dr Robin Proctor, the RCR's m edical director responsible for professional practice and clinical radiology. Consultants Leaving Earlier Staff retention is worsening, with experienced consultants leaving the NHS at younger ages. In 2024, the median age of consultant clinical radiologists leaving the NHS workforce was 50 – down from 56 in 2020. Four in five (79%) of leavers were under 60, and two in five (42%) were under 45. Clinical oncologists followed a similar trend. Their median exit age dropped to 54, from 57 in 2023 and 59 in 2022. Nearly 76% of leavers were under 60, and 26% were under 45. One consultant clinical oncologist told the college that delays in scans and treatment were resulting in missed or late cancer diagnoses. Some patients' conditions were deteriorating or reaching a stage where treatment was no longer possible. Changing Work Practices 'Working conditions and ways of working need to change if we are to address this problem and meet the growing demand for our expertise,' Proctor said. The RCR has called on the government to invest in training and recruitment. In 2024, the NHS spent an estimated £325 million on temporary radiology staff. The cost of outsourcing had doubled since before the COVID-19 pandemic and had surged by almost a quarter in the past year. The RCR estimated that increasing radiology trainee numbers by 50% could eliminate three-quarters of the current shortfall and save the NHS £460 million over the next 10 years. 'Patients are being failed by a chronic lack of radiologists and oncologists,' said RCR president Dr Katharine Halliday. 'The longer we delay action, the worse it gets,' she added.
Yahoo
2 days ago
- Yahoo
WVU Medicine Princeton Community Hospital breaks ground on PCH Bluefield campus
BLUEFIELD, WV (WVNS) – WVU Medicine continues to expand with the breaking of ground for the new Bluefield campus of Princeton Community Hospital. Located on Southview Drive, the $25 million facility will offer state-of-the-art care to residents in the area. The location will be home to the Bluefield Emergency Department and PCH Behavioral Health Center, and the expansion itself is part of an effort by WVU Medicine to offer comprehensive access and care to patients no matter where they are in the state, according to Princeton Community Hospital President and CEO, Karen Bowling.'One reason WVU Medicine has expanded is we want to make sure we are serving the entire community and that it is a comprehensive level of care,' she said. 'If you think about it, we're on the same medical record. Whether you're in Princeton or you're in Bluefield, whether you need to go to Ruby to have a bone marrow transplant – we're all on the same medical record.'Bowling said the expansion is about communities, families, and serving the region as well as the state. 'As someone who grew up in this region, I know firsthand how much this investment means,' she continued. 'This project is about more than bricks and mortar; it's about giving our families, friends, and neighbors access to the kind of care they deserve, right here at home. WVU Medicine is making a promise to this region, and I'm proud to be part of delivering on that promise.' WVU Medicine President & CEO, Albert Wright reiterated the importance of widespread coverage under a single umbrella as it pertains to patient care. 'This project exemplifies WVU Medicine's unwavering investment in delivering high-quality, accessible care to West Virginians,' he said. 'By expanding services and upgrading facilities, like here at the Bluefield Campus, we're not only enhancing patient care, but we're also reinforcing our long-term commitment to advancing health outcomes in southern West Virginia.'Features of the Bluefield campus will include: The new emergency department (ED) will include: 20 exam rooms, including two rooms designed for psychiatric intake Two resuscitation rooms and two triage rooms OB-ready and trauma rooms Centralized care team support stations Dedicated patient and ambulance entrances Diagnostic Radiology — two radiology rooms Computed Tomography (CT) — one CT scanner Magnetic Resonance Imaging (MRI) — one MRI scanner (a new service for Bluefield) Ultrasound — two ultrasound rooms (a new service for Bluefield) Guest speakers and live music were part of the groundbreaking celebration as guests got their first look at plans for the new facility. PCH plans to officially open the doors to its Bluefield campus in the Fall of 2027, as the provider hopes to further extend the scope of patient accessibility and care. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
